INDP
Indaptus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Ample Liquidity
Bearish Abandoned Baby
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INDP
Indaptus Therapeutics, Inc.
A pharmaceutical company that develops therapy based on the hypothesis that efficient actiation of both innate and adaptive immune cells
3 Columbus Circle, 15th Floor, New York, NY, 10019
--
Indaptus Therapeutics, Inc., was incorporated in Delaware on February 24, 2021. This is a clinical-stage biopharmaceutical company developing a novel, patented system-delivered anticancer and antiviral immunotherapy. Indaptus' patented technology consists of a single strain of attenuated and killed non-pathogenic gram-negative bacteria with reduced intravenous toxicity, but largely with the uncompromising ability to stimulate or activate many cellular components of innate and adaptive immunity. This approach produces a wide range of anti-tumor and antiviral activities, including safe, long-lasting synergistic effects of anti-tumor responses with five different existing drugs, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Eradication of tumors through Indaptus technology has demonstrated activation of innate and adaptive immune memory, and importantly, there is no need to provide or target tumor cells in preclinical models. Indaptus has successfully produced GMP for its lead clinical candidate, Decoy 20, and is currently completing other IND-enabling studies.
Company Financials
EPS
INDP has released its 2025 Q3 earnings. EPS was reported at -2.98, versus the expected -4.17, beating expectations. The chart below visualizes how INDP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
